FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer
| العنوان: | FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer |
|---|---|
| المؤلفون: | Godefridus J. Peters, Alfredo Falcone, Elisa Giovannetti, Enrico Vasile, Chiara Caparello, Niccola Funel, Tessa Y S Le Large, Ingrid Garajová, Geert Kazemier, Laura L. Meijer |
| المساهمون: | Medical oncology laboratory, Surgery, CCA - Target Discovery & Preclinial Therapy Development, Caparello, Chiara, Meijer, Laura L., Garajova, Ingrid, Falcone, Alfredo, Le Large, Tessa Y., Funel, Niccola, Kazemier, Geert, Peters, Godefridus J., Vasile, Enrico, Giovannetti, Elisa |
| المصدر: | World Journal of Gastroenterology 22 (2016): 6987–7005. doi:10.3748/wjg.v22.i31.6987 info:cnr-pdr/source/autori:Caparello C.; Meijer L.L.; Garajova I.; Falcone A.; Le Large T.Y.; Funel N.; Kazemier G.; Peters G.J.; Vasile E.; Giovannetti E./titolo:FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer/doi:10.3748%2Fwjg.v22.i31.6987/rivista:World Journal of Gastroenterology/anno:2016/pagina_da:6987/pagina_a:7005/intervallo_pagine:6987–7005/volume:22 World Journal of Gastroenterology, 22(31), 6987-7005. WJG Press Caparello, C, Meijer, L L, Garajova, I, Falcone, A, Le Large, T Y, Funel, N, Kazemier, G, Peters, G J, Vasile, E & Giovannetti, E 2016, ' FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer ', World Journal of Gastroenterology, vol. 22, no. 31, pp. 6987-7005 . https://doi.org/10.3748/wjg.v22.i31.6987Test |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, Vascular Endothelial Growth Factor A, medicine.medical_specialty, Organoplatinum Compounds, FOLFIRINOX, Leucovorin, Review, Personalized therapy, Pharmacology, Irinotecan, Translational Research, Biomedical, 03 medical and health sciences, 0302 clinical medicine, New treatments, Pancreatic cancer, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, New treatment, Precision Medicine, MicroRNA, Gastroenterology, business.industry, Standard treatment, General Medicine, medicine.disease, Precision medicine, Gemcitabine, Oxaliplatin, ErbB Receptors, Pancreatic Neoplasms, Regimen, 030104 developmental biology, 030220 oncology & carcinogenesis, Camptothecin, Fluorouracil, business, medicine.drug |
| الوصف: | Pancreatic cancer is an extremely aggressive disease; although progress has been made in the last few years, the prognosis of these patients remains dismal. FOLFIRINOX is now considered a standard treatment in first-line setting, since it demonstrated an improved overall and progression-free survival vs gemcitabine alone. However, the enthusiasm over the benefit of this three-drug regimen is tempered by the associated increased toxicity profile, and many efforts have been made to improve the feasibility of this schedule. After a more recent phase III trial showing an improved outcome over gemcitabine, the combination of gemcitabine/nab-paclitaxel emerged as another standard first-line treatment. However, this treatment is also associated with more side effects. In addition, despite initial promising data on the predictive role of SPARC levels, recent studies showed that these levels are not associated with nab-paclitaxel efficacy. The choice to use this treatment over FOLFIRINOX is therefore a topic of debate, also because no validated biomarkers to guide FOLFIRINOX treatment are available. In the era of actionable mutations and target agents it would be desirable to identify molecular factors or biomarkers to predict response to therapy in order to maximize the efficacy of treatment and avoid useless toxic effects for non-responding patients. However, until today the milestone of treatment for pancreatic cancer remains chemotherapy combinations, without predictive or monitoring tools existing to optimize therapy. This review analyzes the state-of-the-art treatments, promises and limitations of targeted therapies, ongoing trials and future perspectives, including potential role of microRNAs as predictive biomarkers. |
| وصف الملف: | STAMPA |
| اللغة: | English |
| تدمد: | 1007-9327 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f160b44d37da70d97792b23f6f1f5449Test http://hdl.handle.net/11568/828160Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....f160b44d37da70d97792b23f6f1f5449 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 10079327 |
|---|